Abstract
SM Jones, SH Sicherer, AW Burks; Consortium of Food Allergy Research. J Allergy Clin Immunol. 2017;139(4):1242–1252.e9 To evaluate the clinical, safety, and immunologic effects of epicutaneous immunotherapy (EPIT) for the treatment of peanut allergy. The study included 74 patients ages 4–25 years with a peanut allergy, defined as physician-diagnosed or as the patient having a convincing clinical history of a peanut allergy, a positive result on a peanut skin prick test, or peanut-specific IgE and a positive entry oral food challenge (OFC) to 1044 mg of peanut protein or less. Children with a history of severe anaphylaxis were excluded. Participants were randomly assigned to double-blind peanut EPIT …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
